Table 2. Focused miRNA panel – miRNAs significantly associated with time to disease progression.
Screening CAPEOXBEV cohort | Validation CAPEOXBEV cohort | Combined CAPEOXBEV cohort | Control CAPEOX cohort | Interactiona | |||||||||||
n = 155 | n = 121 | n = 276 | n = 127 | all | distal | proximal | |||||||||
miRNA | HRb | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | P | P | P |
Raw expression values | |||||||||||||||
miR-15a-5p | 0.88 | 0.73–1.06 | 0.19 | 0.73 | 0.54–0.98 | 0.04 | 0.86 | 0.73–1.00 | 0.05 | 1.03 | 0.80–1.31 | 0.84 | 0.14 | 0.25 | 0.15 |
miR-17-3p | 0.68 | 0.54–0.84 | 0.0005 | 0.92 | 0.68–1.23 | 0.57 | 0.77 | 0.64–0.91 | 0.003 | 1.01 | 0.78–1.31 | 0.92 | 0.16 | 0.11 | 0.67 |
miR-193b-5p | 0.82 | 0.70–0.95 | 0.01 | 0.74 | 0.54–1.01 | 0.06 | 0.82 | 0.72–0.94 | 0.004 | 0.92 | 0.77–1.10 | 0.34 | –c | – | – |
miR-204-5p | 0.83 | 0.71–0.96 | 0.02 | 0.92 | 0.68–1.23 | 0.56 | 0.83 | 0.71–0.97 | 0.02 | 0.90 | 0.71–1.14 | 0.38 | 0.86 | 0.60 | 0.25 |
miR-501-5p | 0.78 | 0.63–0.97 | 0.03 | 0.88 | 0.63–1.23 | 0.46 | 0.81 | 0.66–0.99 | 0.04 | 0.96 | 0.69–1.32 | 0.78 | 0.48 | 0.47 | 0.84 |
miR-545-3p | 0.87 | 0.77–1.00 | 0.04 | 0.87 | 0.73–1.05 | 0.15 | 0.86 | 0.77–0.96 | 0.005 | 1.00 | 0.88–1.14 | 0.97 | 0.11 | 0.17 | 0.29 |
miR-592 | 0.71 | 0.54–0.93 | 0.01 | 0.80 | 0.62–1.01 | 0.06 | 0.77 | 0.67–0.90 | 0.0007 | 0.81 | 0.58–1.12 | 0.21 | 0.14 | 0.11 | 0.82 |
miR-664-3p | 0.87 | 0.66–1.15 | 0.32 | 0.60 | 0.41–0.87 | 0.007 | 0.80 | 0.65–0.99 | 0.04 | 0.81 | 0.58–1.13 | 0.21 | 0.10 | 0.04 | 0.31 |
Mean-normalized expression values | |||||||||||||||
miR-17-3p | 0.78 | 0.63–0.98 | 0.03 | 1.05 | 0.83–1.34 | 0.68 | 0.89 | 0.76–1.05 | 0.16 | 1.10 | 0.82–1.48 | 0.52 | 0.22 | 0.09 | 0.26 |
miR-155-5p | 1.36 | 1.07–1.71 | 0.01 | 1.33 | 1.00–1.77 | 0.05 | 1.38 | 1.15–1.64 | 0.0005 | 1.05 | 0.79–1.38 | 0.74 | 0.05 | 0.18 | 0.18 |
miR-185-5p | 1.45 | 1.17–1.80 | 0.0008 | 1.23 | 0.87–1.74 | 0.24 | 1.30 | 1.10–1.54 | 0.003 | 0.89 | 0.67–1.19 | 0.44 | 0.06 | 0.20 | 0.43 |
miR-204-5p | 0.82 | 0.68–0.98 | 0.03 | 1.13 | 0.87–1.46 | 0.38 | 0.90 | 0.78–1.03 | 0.13 | 0.95 | 0.79–1.13 | 0.54 | 0.15 | 0.07 | 0.14 |
miR-449a | 1.25 | 1.03–1.52 | 0.02 | 0.97 | 0.73–1.28 | 0.81 | 1.15 | 0.99–1.35 | 0.07 | 1.00 | 0.80–1.26 | 0.96 | 0.55 | 0.89 | 0.74 |
Interaction tests were performed for all patients and for patients with distal (sigmoid and rectum) and proximal (cecum to descending) primary tumor location, separately.
Hazard ratio is per inter-quartile range expression increase and is adjusted for age, sex, number of metastatic sites, prior adjuvant treatment and primary tumor location.
miRNA was missing in >10% of samples so interaction was not tested.
Abbreviations: HR, hazard ratio; CI, confidence interval.